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Clinical Patterns of Hepatocellular
Carcinoma in Nonalcoholic Fatty Liver
Disease: A Multicenter Prospective Study
Fabio Piscaglia,1 Gianluca Svegliati-Baroni,2 Andrea Barchetti,3 Anna Pecorelli,1 Sara Marinelli,1 Claudio Tiribelli,3,4 and
Stefano Bellentani3; on behalf of the HCC-NAFLD Italian Study Group*
Nonalcoholic fatty liver disease (NAFLD) represents the hepatic manifestation of metabolic syndrome and may evolve
into hepatocellular carcinoma (HCC). Only scanty clinical information is available on HCC in NAFLD. The aim of this
multicenter observational prospective study was to assess the clinical features of patients with NAFLD-related HCC
(NAFLD-HCC) and to compare them to those of hepatitis C virus (HCV)-related HCC. A total of 756 patients with
either NAFLD (145) or HCV-related chronic liver disease (611) were enrolled in secondary care Italian centers. Survival
was modeled according to clinical parameters, lead-time bias, and propensity analysis. Compared to HCV, HCC in
NAFLD patients had a larger volume, showed more often an infiltrative pattern, and was detected outside specific surveil-
lance. Cirrhosis was present in only about 50% of NAFLD-HCC patients, in contrast to the near totality of HCV-HCC.
Regardless of tumor stage, survival was significantly shorter (P 5 0.017) in patients with NAFLD-HCC, 25.5 months
(95% confidence interval 21.9-29.1), than in those with HCV-HCC, 33.7 months (95% confidence interval 31.9-35.4). To
eliminate possible confounders, a propensity score analysis was performed, which showed no more significant difference
between the two groups. Additionally, analysis of patients within Milan criteria submitted to curative treatments did not
show any difference in survival between NAFLD-HCC and HCV-HCC (respectively, 38.6 versus 41.0 months, P 5 non-
significant) Conclusions: NAFLD-HCC is more often detected at a later tumor stage and could arise also in the absence of
cirrhosis, but after patient matching, it has a similar survival rate compared to HCV infection; a future challenge will be
to identify patients with NAFLD who require more stringent surveillance in order to offer the most timely and effective
treatment. (HEPATOLOGY 2016;63:827-838)
H
epatocellular carcinoma (HCC) is among
the five top-ranking causes of cancer death
worldwide.(1) Its occurrence is frequently
associated with fibrotic or cirrhotic chronic liver disease
whose main etiology is either viral infection, hepatitis
B virus or hepatitis C virus (HCV), or alcohol
abuse.(2-4) Autoimmune and biliary diseases account
for a lower number of cases.
In recent years, an emerging role has been recog-
nized for nonalcoholic fatty liver disease (NAFLD) as
a cause of chronic liver disease progressing to nonalco-
holic steatohepatitis (NASH) and cirrhosis. NAFLD
encompasses a large spectrum of features, ranging from
simple reversible steatosis to the presence of inflamma-
tion and/or fibrosis, which can progress to cirrhosis
and HCC.(5) NAFLD represents the hepatic manifes-
tation of the metabolic syndrome, and its prevalence is
growing rapidly, especially in Western countries in
parallel with the epidemic proportions of obesity and
type 2 diabetes mellitus. NAFLD is almost always
associated with the presence of insulin resistance and
type 2 diabetes mellitus.(6-8) On the other hand, the
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most frequent type of cancer in type 2 diabetes has
been shown to be HCC,(9) and obesity almost doubles
the risk of HCC.(10,11) Therefore, a rapidly increasing
incidence of NAFLD-HCC may be expected in the
coming years.(12)
Only scant information exists about the clinical fea-
tures and survival outcome of HCC on NAFLD, and
a comparison with the features of HCC in viral hepati-
tis has not been satisfactorily addressed. Hence,
whether HCC on NAFLD follows a similar outcome
course to HCC on HCV is still a matter of debate.
The aim of the present study was to assess the survival
outcomes of patients with NAFLD-HCC and to com-
pare them to those of patients having HCV-related
HCC, all enrolled in the same period.
Patients and Methods
This is a prospective, multicenter, comparative
observational study of consecutive patients with HCC
enrolled in secondary care Italian centers, between
2010 and the end of 2012. The majority of the partici-
pating centers belong to the ITA.LI.CA. Study
Group,(13) but the study was not restricted as other
centers were invited to participate. The ethical com-
mittees of the participating hospitals approved the
study. The protocol is consistent with the principles of
the Declaration of Helsinki and was approved by the
Fatty Liver Inhibition of Progression Consortium
Board of Review (see http://www.flip-fp7.eu).
Enrollment in each study center took place when a
patient with HCC was seen at the center between Jan-
uary 1, 2010, and December 31, 2012, either at the
first HCC diagnosis or at any time during the course
of the neoplastic disease. The inclusion criterion was
the presence of HCC diagnosed according to the latest
international guidelines in connection with the time of
patient observation.(14,15) These guidelines foresee the
possibility of an imaging diagnosis in patients with cir-
rhosis and the need for histological confirmation only
in those without cirrhosis (or those with an uncertain
diagnosis after imaging procedures).
Patients were classified as having NAFLD if all
other known etiologies of liver disease could be ruled
out and if consistent present or past histological or
ultrasonographic features of fatty liver and alcohol
intake <30 g/day were present.(16) Fibrosis in NAFLD
patients was categorized according to the Kleiner
classification.(17)
Patients with a history of alcohol abuse (defined as a
chronic alcohol intake exceeding 30 g/day) as well as
those with hepatitis B surface antigen positivity, anti-
body to hepatitis B core antigen positivity, or antibody
to hepatitis B surface antigen positivity in the absence
of a history of vaccination or with chronic intake of
fatty liver-inducing drugs were excluded from the
study. Patients with concurrent active non-HCC liver
cancer, either primary or metastatic, were also
excluded.
The diagnosis of cirrhosis was based either on his-
tology or on clinical, ultrasound, endoscopic, and/or
laboratory assessment.
Metabolic syndrome was diagnosed if at least three
of the following five criteria were present(18):
 Body mass index 25, with waist circumference
94 cm in men and 88 cm in women
 Fasting glucose 110 mg/dL or a diagnosis of type
2 diabetes
 Triglycerides 1.7 mmol/L (150 mg/dL)
 High-density lipoprotein cholesterol <1.0 mmol/
L (40 mg/dL; men) or <1.3 mmol/L (50 mg/
dL; women)
 Blood pressure 130/85 mm Hg or ongoing
antihypertensive therapy
The final study group consisted of 145 patients with
NAFLD-HCC. The control group consisted of 611
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patients with purely HCV-related HCC and was
obtained from the ITA.LI.CA centers database. The
enrollment period of the control groups was the same
(2010-2012) as that of NAFLD-HCC.
Information regarding the metabolic profile (includ-
ing diabetes, arterial hypertension, triglyceridemia,
cholesterolemia, signs of atherosclerosis), tumor bur-
den (number and size of the largest nodule, infiltrative
forms), liver function tests, alpha-fetoprotein level, and
type of treatment was recorded at the time of observa-
tion in the study center, while age and type of HCC
detection were recorded at the time of the first HCC
diagnosis.
We considered as the first treatment the one per-
formed at the entry into the study when also the demo-
graphic and clinical variables were collected. Survival
was calculated accordingly. Treatment was selected in
line with the current guidelines(15) and according to
the clinical, biochemical, and oncologic characteristics
of the patients. Liver function tests, serum virological
markers, metabolic profile, and alpha-fetoprotein were
measured by conventional methods, using commercial
kits.
Treatment was categorized as “best supportive care”
when no oncologic treatment was used, when patients
were enrolled in randomized controlled trials including
a placebo, or when patients received oncologic treat-
ment different from sorafenib (as either a hormonal or
a chemotherapeutic first-line or second-line treat-
ment). When combined locoregional treatments were
used, the patient was classified according to the most
radical treatment.
STATISTICAL ANALYSIS
Continuous variables are expressed as means and
standard deviations or medians and interquartile ranges
as appropriate after testing for normal distribution
using the Kolmogorov-Smirnov test and categorical
variables, as the number of cases and proportions.
Quantitative variables were compared using the Stu-
dent t test, and categorical variables were compared
using the Fisher’s exact test, as appropriate. For the
present study liver function was categorized according
to the Child-Pugh classification(19) also in patients
without a clear demonstration of cirrhosis.
Survival was measured as the interval between the
first visit to the referral center and the last follow-up
visit or death. It was calculated using the Kaplan-
Meier method, reported as mean (95% confidence
interval [CI]) and compared by means of the log-rank
test.
Lead-time bias is the bias caused by the amount of
time by which the diagnosis is advanced because of the
surveillance program. To minimize this effect, which
could possibly be the result of an unbalance in the
number of cases with a diagnosis of HCC under sur-
veillance in the two groups, we calculated the lead
time, using the formula E(s) 5 (1-ekt)/k, as explained
in detail elsewhere.(20)
Propensity analysis was carried out using logistic
regression in order to create a propensity score for
NAFLD and HCV patients. The variables entered
into the propensity model were age, sex, surveillance,
size of the largest nodule, number of nodules, Child-
Pugh score, and type of treatment. This model was
then used to provide a one-to-one match between
NAFLD-HCC and HCV-HCC patients using the
nearest-neighbor matching method. The survival anal-
ysis was repeated in each matched subgroup in order to
assess the impact of etiology on mortality due to con-
founding factors.
Missing values were extremely limited and were
replaced by means or median values. Survival informa-
tion was retrieved by enquiring about the living status
or date of death from the municipality offices of the
towns of residence.
A two-tailed P value <0.05 was considered statisti-
cally significant. All statistical analyses were carried out
using the SPSS 13.0 statistical package (SPSS Inc.,
Chicago, IL). Cumulative incidence rates of competing
events were calculated using the Fine and Gray
method. Competing risk analysis was done using the
package “cmprsk” for R (v2.13.0; R Foundation for
Statistical Computing, Vienna, Austria).
Results
PATIENT CHARACTERISTICS
The demographic and clinical characteristics of
patients are reported in Tables 1 and 2. NAFLD was
confirmed by histology in 40 of the 145 patients
(27.6%). Cirrhosis was detected in 78 of 145 NAFLD
patients (53.8%); 24 (17%) were histologically con-
firmed (including 21 patients with established cirrhosis
and three patients with bridging fibrosis) and in 594
HCV patients (97.2%; 52 of the 594 [9%] were histo-
logically confirmed). The remaining 16 NAFLD
patients without cirrhosis, as proven by histology,
showed the absence of any fibrosis in three (7.5% of
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total NAFLD with histology), mild to minimal fibrosis
in two (5.0%), and moderate fibrosis in 11 (27.5% of
histologically confirmed NAFLD patients). In the
remaining cases of NAFLD, the diagnosis of cirrhosis
was reached by clinical, ultrasonographic, elastographic,
and laboratory findings as accepted by the American
Association for the Study of Liver Diseases guide-
lines.(16) In order to confirm that the 51 patients with-
out histology-proven cirrhosis were free from an
advanced fibrotic stage, we calculated the aspartate
aminotransferase-to-platelet ratio index (APRI)
score.(20) A total of 36 of 51 (71%) patients showed an
APRI score <0.7, confirming nonsevere fibrosis; four
(8%) showed an APRI score between 0.7 and 1.0, con-
sistent with less certainty about the severity of fibrosis,
whereas only 14 (27%) showed an APRI score >1.0,
which would suggest severe fibrosis or cirrhosis, espe-
cially for scores >2.(20)
In summary, the absence of cirrhosis could be clearly
proven by either histology or APRI score <0.7 in 47
(70%) of the 67 NAFLD-HCC patients judged as not
having cirrhosis by the enrolling investigator based on
clinical criteria, confirming the reliability of clinical
judgment.
Patients with NAFLD-HCC were significantly
(P < 0.0001) younger (67.8 6 9.0 versus 71.1 6 9.5
years) and were more often male than patients
with HCV-related HCC (Table 1). They were also
more often smokers and alcohol (<30 g/day)
drinkers. As expected, the metabolic risk factors were
more often present in NAFLD patients than in those
with HCV-related HCC (Table 1), and liver func-
tion tests were significantly less severe in NAFLD
patients than in HCV patients (Table 1). In HCV-
related HCC patients, HCC was diagnosed
more frequently during surveillance (Table 2) than in
TABLE 1. Demographic, Clinical, and Liver Function Characteristics of the Study Populations
Variable HCC on NAFLD (n 5 145) HCC on HCV (n 5 611) P*
Demographic and clinical
Age in years (mean, SD) 67.8 (9.0) 71.1 (9.5) <0.0001
Male gender (n and percent of patients) 115 (79.3%) 374 (61.2%) <0.0001
Body mass index (mean, SD) 29.1 (5.0) 27.6 (4.4) 0.430
Alcohol (n and percent of drinkers) 66 (45.5%) 41(8.6%) <0.0001
Tobacco (n and percent of smokers) 84 (60.9%) 108 (23.8%) <0.0001
Metabolic risk factors†
Diabetes (n and percent of patients) 106 (73.1%) 148 (24.9%) <0.0001
Hypertension (n and percent of patients) 106 (73.1%) 204 (37.1%) <0.0001
Hypertriglyceridemia (n and percent of patients) 37 (25.7%) 17 (3.8%) <0.0001
Hypercholesterolemia (n and percent of patients) 47 (32.9%) 34 (7.3%) <0.0001
Atherosclerosis (n and percent of patients) 44 (31.0%) 89 (19.1%) 0.004
Ischemic cardiomyopathy (n and percent of patients) 18 (12.4%) 47 (8.5%) 0.151
Blood glucose (mg/dL; mean and SD) 124.3 (61.2) 108.0 (39.6) <0.0001
LDL cholesterol (mg/dL; mean and SD) 90.1 (44.79) 94.5 (43.0) 0.516
HDL cholesterol (mg/dL; mean and SD) 46.9 (24.9) 43.3 (16.5) 0.204
Triglycerides (mg/dL; mean and SD) 150.3 (163.2) 104.4 (48.5) <0.0001
Liver function
Bilirubin (mg/dL; mean and SD) 1.1 (0.7) 1.6 (2.2) 0.013
Albumin (g/dL; mean and SD) 4.8 (6.4) 3.9 (3.6) 0.015
International normalized ratio (mean and SD) 1.2 (0.4) 1.0 (0.5) <0.0001
Child-Pugh score (median and range)‡ 5.6 (5-11) 5.8 (5-12) 0.154
MELD score (median and range) 8.3 (3-28) 9.0 (3-24) 0.136
ECOG PS 2 (n and percent of patients) 22 (16.9%) 90 (16.8%) 1.000
Clinical hepatic encephalopathy (n and percent of patients) 7 (4.9%) 31 (5.1%) 1.000
Ascites (n and percent of patients) 32 (22.2%) 196 (36.7%) 0.009
CTP 5-6 (n and percent of patients) 107 (82.3%) 366 (68.1%) 0.001
CTP 7-9 (n and percent of patients) 20 (13.8%) 151 (24.7%) 0.002
CTP 10 (n and percent of patients) 3 (2.3%) 20 (3.7%) 0.595
*P value was assumed to be significant when <0.05.
†Hypertriglyceridemia was assigned if plasma triglycerides >150 mg/dL. Hypercholesterolemia was assigned if total cholesterol >200
mg/dL. Atherosclerosis was assigned if any imaging technique detected arterial atherosclerotic plaques. Ischemic cardiomyopathy was
assigned if clinical history comprised one or more episodes of documented ischemic cardiomyopathy.
‡Among patients in Child-Pugh B class, nine of 20 NAFLD and 71 of 151 HCV patients had a specific score of B7.
Abbreviations: CTP, Child-Turcotte-Pugh score; ECOG PS, Eastern Cooperative Oncology Group Performance Status; HDL, high-
density lipoprotein; LDL, low-density lipoprotein; MELD, Model for End-Stage Liver Disease; SD, standard deviation.
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those with NAFLD, in whom HCC was detected
either at the appearance of symptoms or by hepatic
ultrasound performed without previous history or
clinical signs of chronic liver disease. Thus, HCC
was diagnosed during specific surveillance or periodic
ultrasound in 387 (63.3%) HCV patients versus 69
(47.7%) NAFLD patients, P < 0.0001. A total of
14.9% of HCV patients had experienced at least one
attempt at treatment with antivirals (interferon-based
regimens).
Small HCC (i.e., single HCC <5 cm or two or
three nodules all <3 cm) and Barcelona Clinic Liver
Cancer 0(15) were less frequent in NAFLD-HCC than
in HCV-related HCC patients (Table 2). Conversely,
advanced-stage Barcelona Clinic Liver Cancer C
HCC or infiltrative HCC was significantly (P <
0.0001) more common in NAFLD patients (infiltra-
tive HCC: 21% versus 4% in NAFLD and HCV,
respectively).
Patients with HCV infection had worse liver func-
tion in comparison to NAFLD patients; in particular,
Child-Pugh class A, with a score of either 5 or 6, was
observed in 366 (68.1%) HCV versus 107 (82.3%)
NAFLD patients (P 5 0.001; Table 1).
Different patterns of tumor burden and liver func-
tion led to partially different treatment allocations in
the two groups (Table 3). More patients with
NAFLD-HCC than HCV-HCC were eligible for
liver resection (19.3% versus 10.6%, P 5 0.002), but
more also underwent only supportive care/unproven





(n 5 611) P
Modality of initial tumor detection
Surveillance (n and percent of patients) 69 (47.6%) 387 (63.3%) 0.001
Case findings (n and percent of patients) 56 (38.6%) 150 (24.6%) 0.001
Symptomatic (n and percent of patients) 20 (13.8%) 45 (7.4%) 0.056
Not specified 0 29 (4.7%)
Tumor characteristics at observation in the study center
Size of largest tumor (cm; mean and SD) 4.1 (2.6) 3.3 (2.9) 0.003
Number of nodules (mean and SD) 1.8 (1.6) 1.6 (1.5) 0.080
Milan In (n and percentage of patients) 80 (55.2%) 418 (68.4%) 0.005
Milan Out (n and percentage of patients) 65 (44.8%) 193 (31.6%) 0.005
Barcelona Clinic Liver Cancer
Stage 0 0 68 (11.1%) <0.0001
Stage A 62 (42.8%) 256 (42.9%) 0.925
Stage B 28 (19.3%) 89 (14.6%) 0.201
Stage C 48 (33.1%) 146 (23.9%) 0.033
Stage D 3 (2.1%) 30 (4.9%) 0.174
Infiltrative (n and percent of patients)* 21 (15.4%) 21 (4.0%) <0.0001
Extrahepatic metastasis (n and percent of patients)* 13 (9.3%) 105 (17.2%) 0.020
Macrovascular infiltration (n and percent of patients)* 25 (17.5%) 87 (14.7%) 0.436
Alpha-fetoprotein (ng/dL; median and range) 7.13 (1.5-83110.2) 20.4 (1-267912) 0.001
*These patients might belong to more than one group (infiltrative and/or extrahepatic spread and/or macrovascular infiltration but all
out of Milan criteria).
P value was assumed to be significant when <0.05.
Abbreviation: Milan In, inside Milan criteria; Milan Out, outside Milan criteria; SD, standard deviation.
TABLE 3. Treatment Strategy in Patients With HCC





(n 5 611) P
Treatment
Liver transplantation 1 (0.7%) 10 (1.6%) 0.700
Surgical resection 28 (19.3%) 65 (10.6%) 0.002
PEI 2 (1.4%) 57 (9.3 %) 0.002
Thermal ablation* 35 (24.1%) 169 (27.6%) 0.915
TACE† 37 (25.5%) 182 (29.8%) 0.606
Sorafenib 4 (2.8%) 53 (8.7%) 0.028
BSC or trials‡ 38 (26.2%) 75 (12.3%) <0.0001
Data are reported as absolute number of patients and percentage
of patients of the total series for each etiology.
*Thermal ablation was carried out in the large majority of cases
by the radiofrequency modality. Very few cases underwent micro-
wave ablation.
†TACE also includes very few patients who underwent yttrium-
90 radiometabolization (four patients withHCV, one patient with
NAFLD).
‡The term “trials” include phase 2 and phase 3 randomized trials
of systemic drug treatments as well as off-label chemotherapeutic
treatments as either first-line or second-line. BSC includes hor-
monal therapy or other therapies of unproven efficacy.
Abbreviations: BSC, best supportive care (could be adopted in
either first-line or second-line treatment for advanced HCC);
PEI, percutaneous ethanol injection; TACE, transarterial
chemoembolization.
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therapies (26.2% versus 12.3%, P < 0.001). Percutane-
ous ethanol injection was adopted more often in HCV
patients (9.3 versus 1.4%, P 5 0.002). However,
the overall rate of patients submitted to curative
treatments (surgical resection, transplantation, or per-
cutaneous ablation) was similar in the two popula-
tions (45.5% versus 49.1% in HCV-HCC, P 5
nonsignificant).
SURVIVAL OUTCOMES
Over a median follow-up of 13 months (interquar-
tile range 5-47), 188 patients died (24.9%), of whom
38 had NAFLD-HCC (26.2% of HCC in NAFLD)
and 150 had HCV-related HCC (24.5%). Crude
mean survival differed statistically between the two
groups, being 27.2 months (95% CI 23.5-30.9) in the
NAFLD patients and 34.4 months (95% CI 32.7-
36.0) in the HCV patients (P 5 0.015). Survival rates
at 1 year and 3 years were 76.4% and 48.7% versus
84.2% and 61.1%, respectively.
These outcomes might theoretically result only from
a later diagnosis in patients not under surveillance or a
later referral of NAFLD-HCC patients to the study
centers with a more advanced tumor stage rather than
to a more aggressive tumor biology.
Because this is a relevant and yet unsolved question,
we adjusted survival for the lead time in patients who
were under surveillance.(13) Mean survival differed stat-
istically between the two groups even after the adjust-
ment, being 25.5 months (95% CI 21.9-29.1) in the
NAFLD patients and 33.7 months (95% CI 31.9-
35.4) in the HCV patients (P 5 0.017). The survival
rate at 1 year and 3 years was 74.7% and 48.3% in the
NAFLD-HCC patients versus 81.5% and 59.5% in
the HCV-HCC patients, respectively.
To clarify further the intrinsic tumor aggressiveness
in the two etiologies, we tried to eliminate possible
confounders such as differences in age, liver function,
and tumor burden, which indeed differed in the two
groups. We therefore ran a propensity score analysis
taking into consideration the main variables with
TABLE 4. Baseline General, Liver, and Tumor Characteristics





(n 5 64) P
Demographic
Age (years; mean and SD) 68.9 (8.4) 69.3 (9.4) 0.83
Male gender (n and percent) 50 (78.1%) 49 (76.6%) 1
Liver function
CTP 5-6 (n and percent) 47 (73.4%) 51 (79.7%) 0.53
CTP 7 (n and percent) 7 (10.9%) 4 (6.2%) 0.53
CTP 8-9 (n and percent) 7 (10.9%) 9 (14.1%) 0.79
CTP 10 (n and percent) 3 (4.7%) 0 0.24
Tumor characteristics
Size largest nodule (cm; mean and SD) 3.2 (1.9) 3.4 (2.0) 0.58
Size 2 cm (n and percent) 24 (37.5%) 23 (35.9%) 1
Size 2.1-3 cm (n and percent) 17 (26.6%) 16 (25.0%) 1
Size 3.1-5 cm (n and percent) 15 (23.4%) 15 (23.4%) 1
Size 5 cm (n and percent) 8 (12.5%) 10 (15.6%) 0.8
Number of nodules: 1 (n and percent) 44 (68.7%) 43 (67.2%) 1
Number of nodules: 2-3 (n and percent) 15 (23.4%) 15 (23.4%) 1
Number of nodules: >3 (n and percent) 5 (7.8%) 4 (6.2%) 1
Infiltrative (n and percent) 1 (1.6%) 3 (4.7%) 0.62
Detection on surveillance (n and percent) 29 (45.3%) 44 (68.7%) 0.12
Treatments
Liver transplantation (n and percent) 1 (1.6%) 1 (1.6%) 1
Surgical resection (n and percent) 14 (21.9%) 17(26.6%) 0.68
PEI (n and percent) 2 (3.1%) 3 (4.7%) 1
Thermal ablation (n and percent) 21 (32.8%) 19 (29.7%) 0.85
TACE (n and percent) 23 (35.9%) 20 (31.2%) 0.71
Sorafenib (n and percent) 0 0
BSC or trials (n and percent) 0 0
Data are reported as absolute number of patients (n) and percentage of patients of the total series for each etiology.
Abbreviations: BSC, best supportive care (could be adopted in either in first-line or second-line treatment for advanced HCC); CTP,
Child-Turcotte-Pugh score; LT, liver transplantation; PEI, percutaneous ethanol injection; SD, standard deviation; TACE, transarte-
rial chemoembolization,
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clinically known impact on survival and showing statis-
tical differences between the two groups (Table 4).
Patients submitted to only supportive care were not
included in this propensity score comparison because
they were few and the reasons for the choice of the
supportive care were most likely heterogenous.
After matching according to the propensity analysis,
there was a smaller, nonsignificant difference in mean
survival between the two groups (30.2 months, 95%
CI 25.3-35.2) in patients with NAFLD-HCC and
36.9 (95% CI 32.6-41.1) in patients with
HCV-related HCC liver-related disease (P 5 0.330).
The survival rates at 1 year and 3 years were 91.9% and
63.3% versus 87.4% and 72.6%, respectively. Because
matching could not include the variable of detection
under surveillance and this was insufficiently repre-
sented in NAFLD patients, we corrected this possible
source of bias by considering the lead time. After
adjustment for lead time, the difference in survival
remained nonsignificant between the two groups: 28.5
months (95% CI 23.7-33.4) in the NAFLD patients
and 35.0 months (95% CI 30.8-39.1) in the HCV
TABLE 5. Baseline Characteristics of the Population Treated With Curative Approaches
Variable NASH (n 5 66) HCV (n 5 269) P
Demographic and clinical
Age (years; SD) 66.4 (10.3) 71.4 (8.8) <0.0001
Male gender 54 (81.8%) 162 (60.2%) 0.001
Surveillance 39 (59.1%) 195 (72.5%) 0.037
Case findings 22 (33.3%) 55 (20.4%) 0.033
Symptomatic 5 (7.6%) 12 (4.5%) 0.345
Body mass index 29.2 (4.5) 28.2 (36.6) 0.723
Alcohol intake 30 (45.4%) 22 (8.2%) <0.0001
Tobacco 34 (51.5%) 54 (20.1%) <0.0001
Metabolic risk factors
Diabetes 48 (72.7%) 60 (22.3%) <0.0001
Hypertension 44 (66.7%) 87 (32.3%) <0.0001
Hypertriglyceridemia 19 (28.8%) 6 (2.2%) <0.0001
Hypercholesterolemia 22 (33.3%) 11 (4.1%) <0.0001
Atherosclerosis 18 (27.3%) 34 (12.6%) 0.001
Ischemic cardiomyopathy 4 (6.1%) 9 (3.3%) 0.043
Glycemia 127.6 (51.6) 101.2 (38.2) <0.0001
LDL cholesterol 88.2 (42.3) 106.6 (41.6) 0.059
HDL cholesterol 51.8 (27.3) 49.1 (16.3) 0.563
Triglyceride 165.6 (203.4) 106.8 (57.3) 0.007
Tumor characteristics
Size of largest tumor (cm) 3.4 (1.7) 2.9 (2.8) 0.135
Size 2 cm 20 (30.3%) 112 (41.6%) 0.049
Size 2.1-3 cm 15 (22.7%) 82 (30.5%) 0.136
Size 3.1-5 cm 22 (33.3%) 36 (13.4%) 0.001
Size 5 cm 9 (13.6%) 23 (8.5%) 0.259
Number of nodules: 1 51 (77.3%) 210 (78.1%) 0.486
Number of nodules: 2-3 14 (21.2%) 43 (16.0%) 0.371
Number of nodules: > 3 1 (1.5%) 5 (1.8%) 1
Milan In 49 (74.2%) 217 (80.7%) 0.010
Milan Out 17 (25.7%) 29 (10.8%) 0.010
Infiltrative 5 (7.6%) 2 (0.7%) 0.005
Metastasis 2 (3.0%) 2 (0.7%) 0.194
Thrombosis 4 (6.1%) 8 (3.0%) 0.265
Liver function
Bilirubin (SD) 0.9 (0.6) 1.2 (0.9) 0.017
Albumin (SD) 4.8 (5.0) 3.8 (2.8) 0.171
INR (SD) 1.3 (0.4) 1.0 (0.5) <0.0001
Alpha-fetoprotein (SD) 371.5 (1601.7) 242.6 (1925.6) 0.634
CTP 5.6 (1.2) 5.5 (1.9) 0.536
ECOG 2 5 (7.6%) 17 (6.3%) 0.783
Encephalopathy 1 (1.5%) 8 (3.0%) 1
Ascites 10 (15.1%) 57 (21.2%) 0.224
Abbreviations: CTP, Child-Turcotte-Pugh score; ECOG, Eastern Cooperative Oncology Group; HDL, high-density lipoprotein;
INR, international normalized ratio; LDL, low-density lipoprotein; Milan In, inside Milan criteria; Milan Out, outside Milan criteria;
SD, standard deviation.
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patients (P 5 0.344). The survival rates at 1 year and 3
years were 85.4% and 63.9% versus 92.2% and 63.7%,
respectively, which were also not statistically
significant.
However, a trend toward longer survival in HCV-
HCC remained present in all the analyses, which did
not clarify the question of a potentially greater tumor
aggressiveness of HCC on NAFLD. We therefore
performed an additional analysis selecting comparable
patient populations. We selected patients from the two
HCC groups submitted to curative treatments (surgical
resection, transplantation, percutaneous ablation). For
these patients no difference in survival related to etiol-
ogy was observed (34.2 versus 40.8 months, NAFLD
and HCV-HCC, respectively; P 5 0.073). However,
the two patient populations differed regarding the
tumor burden as NAFLD-HCC patients showed a
higher percentage of tumors 3-5 cm (Table 5) in spite
of no difference in liver function assessed as Child-
Pugh and Model for End-Stage Liver Disease scores
(Table 1). Consequently, we further restricted the sur-
vival analysis to patients submitted to curative
TABLE 6. Baseline Characteristics of the Population Treated With Curative Approaches and
Selected to Be Within the Milan HCC Criteria
Variable NAFLD (n 5 49) HCV (n 5 217) P*
Demographic and clinical
Age (years; SD) 65.6 (9.2) 71.4 (9.1) <0.0001
Male gender 41 (83.7%) 129 (59.4%) 0.002
Surveillance 32 (65.3%) 166 (76.5%) 0.146
Case findings 14 (28.6%) 40 (18.4%) 0.119
Symptomatic 3 (6.1%) 5 (2.3%) 0.167
Body mass index 29.3 (4.6) 27.0 (30.0) 0.368
Alcohol consumption 24 (49.0%) 18 (8.3%) <0.0001
Tobacco 24 (49.0%) 42 (19.3%) <0.0001
Metabolic risk factors†
Diabetes 36 (73.5%) 48 (22.1%) <0.0001
Hypertension 31 (63.3%) 64 (29.5%) <0.0001
Hypertriglyceridemia 13 (26.5%) 4 (1.8%) <0.0001
Hypercholesterolemia 16 (32.6%) 8 (3.7%) <0.0001
Atherosclerosis 13 (26.5%) 25 (11.5%) 0.004
Ischemic cardiomyopathy 3 (6.1%) 8 (3.7%) 0.117
Glycemia 127.5 (54.9) 99.9 (36.0) 0.001
LDL cholesterol 84.6 (45.4) 96.4 (35.2) 0.285
HDL cholesterol 54.3 (31.0) 50.9 (14.3) 0.577
Triglycerides 185.1 (240.8) 106.2 (61.1) 0.054
Tumor burden
Size of largest tumor (cm) 2.6 (0.9) 2.4 (0.9) 0.136
Size 2 cm 20 (40.8%) 107 (49.3%) 0.342
Size 2.1-3 cm 15 (30.6%) 79 (36.4%) 0.509
Size 3.1-5 cm 14 (28.6%) 30 (13.8%) 0.019
Size 5 cm 0 0
Number of nodules: 1 43 (87.7%) 184 (84.8%) 0.823
Number of nodules: 2-3 6 (12.2%) 33 (15.2%) 0.823
Number of nodules: > 3 0 0
Liver function
Bilirubin (SD) 0.9 (0.6) 1.1 (0.8) 0.075
Albumin (SD) 4.6 (4.8) 3.9 (3.1) 0.185
INR (SD) 1.3 (0.5) 1.0 (0.5) 0.001
Alpha-fetoprotein (SD) 9.1 (11.3) 63.7 (226.7) 0.002
CTP 5.6 (1.3) 5.5 (1.8) 0.727
ECOG 2 4 (8.2%) 9 (4.1%) 0.264
Encephalopathy 1 (2.0%) 5 (2.3%) 1
Ascites 6 (12.2%) 48 (22.1%) 0.289
Survival (months) 38.6 41.0 0.839
*P value was assumed to be significant when <0.05.
†Hypertriglyceridemia was assigned if plasma triglycerides >150 mg/dL. Hypercholesterolemia was assigned if total cholesterol >200
mg/dL. Atherosclerosis was assigned if any imaging technique detected arterial atherosclerotic plaques. Ischemic cardiomyopathy was
assigned if clinical history comprised one or more episodes of documented ischemic cardiomyopathy.
Abbreviations: CTP, Child-Turcotte-Pugh score; ECOG, Eastern Cooperative Oncology Group; HDL, high-density lipoprotein;
INR, international normalized ratio; LDL, low-density lipoprotein; SD, standard deviation.
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treatments but who also had tumors within the Milan
criteria, encompassing 74% in the NAFLD-HCC
group and 81% in the HCV-HCC group. This analy-
sis confirmed the absence of any survival differences
between the two groups (Table 6 and Fig. 1) (38.6
months in NAFLD-HCC versus 41.0 months in
HCV-HCC, P 5 nonsignificant).
Finally, we aimed to verify whether other causes of
death besides those related to the liver might have an
impact on the trend toward crude higher mortality in
NAFLD patients. We performed a competitive risk
analysis (Table 7), which confirmed that tumor and
liver-related causes of death were similarly represented
in the two groups, confirming that HCC in NAFLD
is intrinsically not more aggressive than that in HCV
patients. Interestingly, however, NAFLD patients
were more likely to die from either cardiovascular
events, although this cause was altogether marginally
responsible for death (4% versus 1% at 3 years), or
other non-liver-related, noncardiovascular causes cate-
gorized in the database under “other” (11% versus
5.5% at 3 years) (Table 7).
To understand whether the absence of cirrhosis
might have an impact on survival in NAFLD patients,
we compared the survival of NAFLD patients with
and without cirrhosis. Survival curves did not show a sig-
nificant difference, with overall rates of 28.5 months and
34.9 months in HCC patients with and without cirrho-
sis, respectively. To verify whether the better liver func-
tion in NALFD without cirrhosis may have
counterbalanced the larger tumor burden, leading to sur-
vival similar to HCC on NAFLD without cirrhosis, we
assessed both tumor burden and survival in NAFLD-
HCC patients who received curative therapies (surgery
or ablation). Tumor size and survival appeared compara-
ble in the two groups (survival 28.5 months in those
with cirrhosis versus 34.5 in those without, P 5
nonsignificant).
Discussion
The natural history of NAFLD-HCC is still poorly
understood. In particular, comparison of NAFLD-
HCC to HCC related to other etiologies has not been
satisfactorily studied. Comparison with historical series
of patients with underlying viral cirrhosis is not suita-
ble to provide solid data because diagnostic imaging
and treatment modalities were much poorer in the
past.
In the present study based on two series of patients
collected in a recent period of time, we demonstrated
that patients with NAFLD-HCC have a shorter
                                                                 
FIG. 1. Survival curves of patients with HCC in the early stage
(inside Milan criteria) submitted to curative treatments sub-
grouped according to background liver disease (NAFLD or
HCV).
                                                                 
TABLE 7. Competing Risk Analysis of 1-Year, 2-Year, and 3-Year Cumulative Incidence of Death







1-; 2-; 3-year P
HCC 10.7%; 17.1%; 25.7% 10.3%; 16.0%; 22.0% 0.772
Liver failure 4.0%; 9.6% 9.6% 3.4%; 6.5%; 9.2% 0.481
Gastrointestinal bleeding 0.0%; 0.0%; 0.0% 1.0%; 1.2%; 1.2% 0.258
Liver transplantation 1.4%; 1.4%; 1.4% 0.4%; 1.1%; 2.0% 0.900
Cardiovascular events 0.9%; 4.0%; 4.0% 0.0%; 1.0%; 1.0% 0.008
Others 7.9%; 11.6%; 11.6% 3.0%; 3.9%; 5.5% 0.003
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survival than patients with HCV-HCC, mainly
because the former combination is usually detected at a
later stage and with a greater tumor burden and not
because NAFLD-HCC is more aggressive. In fact,
when confounding factors were eliminated, NAFLD-
HCC showed a survival fully comparable to that of
HCV-HCC.
More specifically, tumor burden significantly differs
among the two groups (Table 2), suggesting that the
crude figure of shorter overall survival in NAFLD-
HCC (Fig. 1) should not be regarded as a greater
aggressiveness of the tumor but most likely only a
delayed diagnosis. The later diagnosis could be caused
by the absence of recognized risk factors (absence or
unrecognized cirrhosis), which results in the lack of
any surveillance program in many NAFLD-HCC
patients and consequently to a delayed diagnosis pro-
longed beyond the lead-time bias. We believe this is
the most likely explanation for the shorter overall sur-
vival observed in patients with NAFLD-HCC. In line
with this conclusion is the observation that when
patients were matched according to a propensity score
analysis based on tumor burden and liver function or
when patients at the early tumor stage (Milan In,
inside Milan criteria) were analyzed, the difference in
survival disappeared.
The number of NAFLD patients with infiltrative
HCC was higher than that of HCV patients (15% ver-
sus 2%), but this figure is comparable to previous find-
ings reported in patients with viral hepatitis or with
mixed etiologies not systematically enrolled in HCC
surveillance programs.(21,22) This further suggests late
diagnosis, and hence lack of surveillance strategies, in
patients with NASH, metabolic syndrome, or type 2
diabetes without cirrhosis as the most likely cause for
our findings.(23)
Our data also showed that in almost 50% of cases
HCC arose in the absence of frank cirrhosis, in agree-
ment with previous smaller studies including fewer
than 100 NAFLD-HCC patients.(24-26) The large
majority of cases where histology was available con-
firmed that NAFLD was not simple fatty liver but
rather NASH with moderate fibrosis. However, limi-
tations of our data are that (1) histology was available
only in nearly 30% of NAFLD patients, but unfortu-
nately this limitation can hardly be solved because in
nonsurgical patients a biopsy of nontumoral liver is
often not justified or accepted, and (2) a referral bias
could be present because some of the study centers are
tertiary centers, which, in addition to their own
patients with HCC emerging on surveillance, also
receive patients (either HCV or NAFLD) referred
from other centers, and whether the referral of the two
etiologies is similar cannot be established from our
data.
The prevalence of social alcohol drinkers (>0-30 g/
day) was higher among our NAFLD patients than
among HCV patients (45.5% versus 8.6%). This find-
ing is not surprising as the prevalence of social alcohol
drinkers was estimated to be about 40% worldwide
and around 60%-70% in Western Europe including
Italy.(27) Because most NAFLD patients were pre-
sumably not aware of an ongoing liver disease risk (as
suggested by HCC detected as an incidental finding
in 38% and only 48% of them being under any type of
surveillance), they most likely behaved as social
drinkers, differently from HCV patients, who usually
stop drinking alcohol because they are very concerned
about their liver disease only in consideration of
having chronic hepatitis viral infection, regardless of
the stage.
On the basis of our data, we conclude that
NAFLD-HCC is more often found at a later tumor
stage than HCV-related HCC, ending with an overall
worse prognosis. However, this difference disappears
when patients with NAFLD and HCV are matched
for tumor stage, suggesting that the natural history is
unrelated to the background etiology of liver disease.
These results highlight the need to focus future
research on identifying those patients with NAFLD
who require surveillance in order to establish earlier
diagnosis and offer them treatment, which in our series
appeared to be as effective as that provided for patients
with HCV at an early stage.
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Appendix
The following institutions and related physicians
have cooperated to collect and clinically manage the
study cases: Dipartimento di Scienze Mediche e Chir-
urgiche, Alma Mater Studiorum-Universita di Bolo-
gna, Bologna, Italy: Mauro Bernardi, Maurizio Biselli,
Paolo Caraceni, Marco Domenicali, Francesca Garuti,
Annagiulia Gramenzi, Barbara Lenzi, Donatella Mag-
alotti, Matteo Cescon, Matteo Ravaioli; Unita Opera-
tiva di Chirurgia, Policlinico S. Marco, Zingonia,
Italy: Paolo Del Poggio, Stefano Olmi; Unita di
Medicina Interna e Gastroenterologia, Complesso
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Integrato Columbus, Universita Cattolica di Roma,
Rome, Italy: Gian Ludovico Rapaccini; Unita Opera-
tiva di Medicina, Azienda Ospedaliera Bolognini,
Seriate, Italy: Claudia Balsamo, Maria Anna Di Nolfo,
Elena Vavassori; Dipartimento di Medicina Clinica e
Sperimentale, Universita di Padova, Padua, Italy:
Alfredo Alberti, Luisa Benvegnu, Angelo Gatta;
Dipartimento di Scienze Chirurgiche e Gastroentero-
logiche, Universita di Padova, Padua, Italy: Anna Gia-
comin, Veronica Vanin, Caterina Pozzan, Gemma
Maddalo; Dipartimento di Malattie Apparato Diger-
ente e Medicina Interna, Azienda Ospedaliero-
Universitaria di Bologna, Unita Operativa di Radiolo-
gia, Bologna, Italy: Emanuela Giampalma, Alberta
Cappelli, Rita Golfieri, Cristina Mosconi, Matteo
Renzulli; Unita Operativa di Gastroenterologia, Ospe-
dale Belcolle, Viterbo, Italy: Paola Roselli; Unita Oper-
ativa di Medicina Protetta, Ospedale Belcolle, Viterbo,
Italy: Serena Dell’Isola, Anna Maria Ialungo; Diparti-
mento di Medicina Interna, Unita di Gastroenterolo-
gia, Universita di Genova, Genoa, Italy: Domenico
Risso, Simona Marenco, Giorgio Sammito, Linda
Bruzzone; Unita Operativa di Medicina Interna e Gas-
troenterologia, Universita Cattolica di Roma, Rome,
Italy: Giulia Bosco, Antonio Grieco, Maurizio Pom-
pili, Emanuele Rinninella, Massimo Siciliano; Unita di
Gastroenterologia, Ospedale Sacro Cuore Don Cala-
bria, Negrar, Italy: Maria Chiaramonte; Dipartimento
di Medicina Clinica e Chirurgia, Unita di Gastroenter-
ologia, Universita di Napoli “Federico II,” Naples,
Italy: Maria Guarino; Dipartimento Biomedico di
Medicina Interna e Specialistica, Unita di Gastroenter-
ologia, Universita di Palermo, Palermo, Italy: Calogero
Camma, Marcello Maida, Andrea Costantino, Maria
Rosa Barcellona; Clinica di Gastroenterologia, Uni-
versita Politecnica delle Marche, Ancona, Italy: Laura
Schiada, Stefano Gemini; Dipartimento di Medicina
Interna, Ospedale per gli Infermi di Faenza, Faenza,
Italy: Arianna Lanzi, Giuseppe Francesco Stefanini,
Anna Chiara Dall’Aglio, Federica Mirici Cappa, Ales-
sandra Suzzi, Alessandro Mussetto, Omero Treossi;
Unita di Malattie Infettive ed Epatologia, Azienda
Ospedaliero-Universitaria di Parma, Parma, Italy:
Gabriele Missale, Emanuela Porro; Unita Operativa
Gastroenterologia e Malattie del Ricambio, Azienda
Ospedaliero-Universitaria Pisana, Pisa, Italy: Valeria
Mismas, Caterina Vivaldi.
The HCC-NAFLD Italian Study Group includes
the following members and coauthors: Luigi Bolondi,
Marco Zoli, Alessandro Granito, Daniela Malagotti,
Francesco Tovoli, Franco Trevisani, Laura Venerandi:
Unita di Medicina, Dipartimento di Scienze Mediche
e Chirurgiche, Policlinico S. Orsola-Malpighi, Alma
Mater Studiorum, University of Bologna, Bologna,
Italy; Giovanni Brandi: Department of Experimental,
Diagnostic and Specialty Medicine, University of
Bologna, Sant’Orsola Malpighi Hospital, Bologna,
Italy; Alessandro Cucchetti: Unit of Liver Transplan-
tation, University of Bologna, Sant’Orsola Malpighi
Hospital, Bologna, Italy; Elisabetta Bugianesi, Ester
Vanni, Lavinia Mezzabotta: Divisione di Gastro-
epatologia, Dipartimento di Scienze Mediche, AOU
Citta della Salute, Universita di Torino, Turin, Italy;
Giuseppe Cabibbo, Salvo Petta: Dipartimento Biome-
dico di Medicina Interna e Specialistica, Unita di Gas-
troenterologia, Universita di Palermo, Palermo, Italy;
Anna Fracanzani, Silvia Fargion: Department of
Pathophysiology and Transplantation, Metabolic Liver
Diseases Research Center, Ca’ Granda IRCCS Foun-
dation, Policlinico Hospital Pad Granelli, Milan, Italy;
Fabio Marra, Bernardo Fani: Dipartimento di Medic-
ina Sperimentale e Clinica Universita di Firenze, Flor-
ence, Italy; Elisabetta Biasini: Unita di Malattie
Infettive ed Epatologia, Azienda Ospedaliero-
Universitaria di Parma, Parma, Italy; Rodolfo Sacco:
Unita Operativa Gastroenterologia e Malattie del
Ricambio, Azienda Ospedaliero-Universitaria Pisana,
Pisa, Italy; Filomena Morisco, Nicola Caporaso, Maria
Guarino: Dipartimento di Clinica Medica e Chirurgia,
Universita di Napoli Federico II, Naples, Italy; Mas-
simo Colombo, Roberta D’Ambrosio: Unita Operativa
di Gastroenterologia ed Epatologia, Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico,
Universita degli Studi di Milan, Milan, Italy; Lory S.
Crocè, Riccardo Patti: Centro Studi Fegato, Liver
Research Center-Science Park-Basovizza Campus,
Trieste, Italy; Edoardo G. Giannini: Unita di Gastro-
enterologia, Dipartimento di Medicina Interna,
IRCCS-Azienda Ospedaliera San Martino-IST, Uni-
versita di Genova, Genoa, Italia; Paola Loria, Amedeo
Lonardo, Enrica Baldelli: Dipartimento di Medicina
Metabolica, Universita degli Studi di Modena e
Reggio Emilia-NOCSE-Baggiovara, Modena, Italy;
Luca Miele, Antonio Grieco: Clinical Division of
Internal Medicine, Gastroenterology and Liver Unit,
Institute of Internal Medicine, Policlinico Gemelli
Hospital, Catholic University, Rome, Italy; Fabio
Farinati, Caterina Pozzan: Dipartimento di Scienze
Chirurgiche e Gastroenterologiche, Unita di Gastroen-
terologia, Universita di Padova, Padua, Italy; Mauro
Borzio, Elena Dionigi: Unita di Gastroenterologia,
Azienda Ospedaliera di Melegnano, Vizzolo
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Predabissi, Italy; Giorgio Soardo, Unita Operativa
Gastroenterologia, Ospedale di Udine, Udine, Italy;
Eugenio Caturelli, Paola Roselli: Unita Operativa di
Gastroenterologia, Ospedale Belcolle, Viterbo, Italy;
Francesca Ciccarese: Divisione di Chirurgia, Policli-
nico San Marco, Zingonia, Italy; Roberto Virdone,
Andrea Affronti: U.O.C Medicina 2, A.O. Ospedali
riuniti Villa Sofia, Ospedale Cervello, Palermo, Italy;
Francesco Giuseppe Foschi: Unita di Medicina
Interna, Presidio Ospedaliero di Faenza, Faenza, Italy;
Franco Borzio: Dipartimento di Medicina, Unita di
Radiologia, Ospedale Fatebenefratelli, Milan, Italy.
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